FDA Grants AP Status for Piroxicam ANDA206152 by Micro Labs
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status of 'AP' for Piroxicam submitted by Micro Labs.
Published: August 6, 2026
Updated: August 6, 2026
Author: Humanexa Intelligence
Therapeutic area: Pain Management / NSAID
Company: Micro Labs
Asset: Piroxicam
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Micro Labs
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's granting of AP status for Micro Labs' Piroxicam could significantly alter competitive dynamics within the NSAID market. This development necessitates close monitoring to understand its implications for existing products and market share.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for the final approval and market entry timeline for Micro Labs' Piroxicam product.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.